Europe has been the source of much of scientific development in genomics, however, the adoption of advanced diagnostics in the clinic and healthcare systems is still limited. In this white paper by CRA consultants and The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), the authors discuss barriers, opportunities, and requirements for success.
The authors review the evidence on the value of “advanced diagnostics” and the barriers that impede the development and uptake of advanced diagnostic technologies, and consider the need for an ecosystem that fosters the development of commercial advanced diagnostics and their uptake in the clinical setting.
The authors argue that this effort should be integrated into the multitude of national genomic medicine initiatives that have been established in many countries over the past 15 years.
Click here to read the press release.
To read the entire report, see the original source link above.